Summit Tx Capital, L.P. Halozyme Therapeutics, Inc. Transaction History
Summit Tx Capital, L.P.
- $2.32 Trillion
- Q1 2025
A detailed history of Summit Tx Capital, L.P. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Summit Tx Capital, L.P. holds 4,431 shares of HALO stock, worth $216,897. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,431Holding current value
$216,897% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
595Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$862 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$628 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$296 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$191 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$180 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.82B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...